A Retrospective Review of Contrast Nephropathy in a General Population

Insights

Contrast-induced nephropathy incidence may be overestimated in patients undergoing CT scans. Most cases with elevated creatinine had other contributing risk factors besides contrast media exposure.

Area of Science:

  • Nephrology
  • Radiology
  • Medical Imaging

Background:

  • Contrast-induced nephropathy (CIN) is a known adverse event of intravenous (IV) contrast media.
  • The actual incidence of CIN remains poorly characterized, particularly in patients with pre-existing renal impairment.

Purpose of the Study:

  • To investigate the incidence of CIN in patients with elevated baseline serum creatinine undergoing computed tomography (CT) with IV contrast.
  • To identify other risk factors contributing to elevated serum creatinine in these patients.

Main Methods:

  • Retrospective analysis of electronic medical records from a community hospital.
  • Identified patients with elevated baseline serum creatinine ( > 1.2 mg/dL) who underwent CT with IV contrast media.
  • Assessed for subsequent rise in serum creatinine and identified concomitant risk factors.

Main Results:

  • 193 patients with elevated baseline creatinine underwent 236 CT studies.
  • Nine patients (4.7%) experienced a rise in serum creatinine (≥ 0.5 mg/dL) within one month.
  • None of these nine patients had contrast media exposure as the sole risk factor for elevated creatinine.

Conclusions:

  • The contribution of IV contrast media to nephropathy may be overestimated.
  • Further research is needed to determine if CIN is a common or distinct entity in patients without other risk factors.
  • Routine pretreatment for CIN may not be warranted in all cases, considering risks and costs.
Abstract

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
459
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
953
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
936
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
310
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.3K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
301